November 22, 2022 5:27pm

Also, a bit of a vacation for me with a shortened closing bell’ report

Indication Results: 1 Hit and 2 Miss

News: uniQure N.V. (QURE) announced that its partner, CSL (ASX: CSL), has received approval from the U.S. FDA for HEMGENIX® (etranacogene dezaparvovec-drlb), a one-time gene therapy for the treatment of adults 18 years of age and older living with hemophilia B.

It’s an honor to be considered the “canary in the (sector) coal mine”! It’s more than opinion, the facts and truth need to be recognized!

Ask yourself, do you know why you own certain equity?

 Why do I keep writing this blog/newsletter; to inform investors, what others won’t say or write

 

If I have learned one thing as a former research analyst in a venture and public fund now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +397.82 points (+1.18%), the S&P close UP +53.64 points (+1.36%) while the Nasdaq closed UP +149.90 points (+1.36%)

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes rose Tuesday as markets looked past tightening covid policies in China to instead focus on a host of strong earnings reports and the potential for smaller future rate hikes during a holiday-shortened trading week.

The stock market will be closed on Thursday for the Thanksgiving holiday and will close early on Friday.

 

Tuesday’s … RegMed Investor’s (RMi) Pre-Open: “be mindful of frazzled sector” … https://www.regmedinvestors.com/articles/12711

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened

  • Tuesday’s advance/decline line opened negative at 11 up/ 20 down and 4 flats, flipped positive with 17 up/ 16 down and 2 flats at the mid-day, ending with a positive close of 26/7 and 2 flats.
  • Monday’s advance/decline line opened negative at 11 up/ 23 down and 1 flat, stayed negative with 5 up/ 30 down and 0 flat at the mid-day, ending with a negative close of 4/31 and 0 flat.

 

Pre-open Indications: 1 Hit < Ultragenyx (RARE +$0.28)> 2 Miss <Beam Therapeutics (BEAM +$0012), Biostage (OTCQB: BSTG +$0.05)>

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB was up +0.79% and the XBI was up +1.38%
  • Monday, the IBB was down -0.55% and the XBI was down -1.36%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -1.07 points or -4.79% at 21.29
  • Monday was down -0.77. points or -3.33% at 22.35

 

Q4 – November

  • Tuesday closed positive with 26 incliner, 7 decliners and 2 flats
  • Monday closed negative with 4 incliner, 31 decliners and 0 flats

 

The BOTTOM LINE: I try to keep it simple … and short!

Reiterating from this morning, “be mindful of frazzled sector” … yet, the sector rallied after opening down Tuesday closing near a monthly session high.

With the Thanksgiving holiday muting trading and Fed-critical economic data next week, the market rally could be rangebound in the short run. <IBD>

It’s Thanksgiving Week – escaping to a duck along with turkey accoutrements, apple pie with a pumpkin cheese cake, my way of saying “thanks” – a “yummy tummy”.

NO Happy Thanksgiving to … CEO Sue Washer and president (currently) of Applied Genetic Technologies (AGTC) for her “mistakes in management and judgement” during her tenure (let’s NOT forget her “bored” of directors) – who let her get away with such “gross mis-judgements” to have to sell-out the company for pennies as she executes her “exit package” of $1.5+ million having been paid $1.5 million to “wreck” the company this year.

Key word of the state of uncertainty in “our” universe of cell and gene therapy … “which makes It difficult to predict where sector is headed in the short run.”

Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.